CoraLite® Plus 488-conjugated Alpha Galactosidase A Monoclonal antibody

• Featured Product
• KD/KO Validated

Alpha Galactosidase A Monoclonal Antibody for IF

Host / Isotype

Mouse / IgG2a

Reactivity

human

Applications

IF

Conjugate

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

2B2C5

Cat no : CL488-66121

Synonyms

Alpha D galactosidase A, Alpha galactosidase A, GALA, galactosidase, alpha, GLA, Melibiase

---

Validation Data Gallery

• 

  IF Staining of HepG2 using CL488-66121

  Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using CL488-66121 (Alpha galactosidase A antibody) at dilution of 1:100.

---

Tested Applications

• Positive IF detected in: HepG2 cells

Recommended dilution

• Immunofluorescence (IF): IF : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

The immunogen of CL488-66121 is Alpha Galactosidase A Fusion Protein expressed in E. coli.

• Tested Reactivity: human
• Host / Isotype: Mouse / IgG2a
• Class: Monoclonal
• Type: Antibody
• Immunogen: Alpha Galactosidase A fusion protein Ag7505
• Full Name: galactosidase, alpha
• Calculated Molecular Weight: 49 kDa
• Observed Molecular Weight: 49 kDa
• GenBank Accession Number: BC002689
• Gene Symbol: GLA
• Gene ID (NCBI): 2717
• RRID: AB_2883263
• Conjugate: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 493 nm / 522 nm
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

GLA, also named as Melibiase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.